MedTrace Logo

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

NCT05147272 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2025-12-05

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.

Conditions

  • Adult Solid Tumor

Interventions

DRUG

RP-6306 (oral PKMYT1 inhibitor)

RP-6306 in combination with gemcitabine

Sponsors & Collaborators

  • Repare Therapeutics

    collaborator INDUSTRY

  • Debiopharm International SA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-16
Primary Completion
2024-08-28
Completion
2024-08-28
FDA Drug
Yes

Countries

  • United States
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05147272 on ClinicalTrials.gov